Interdisciplinary Perspectives on the Co-Management of Metabolic Dysfunction-Associated Steatotic Liver Disease and Coronary Artery Disease

TY - JOUR

T1 - Interdisciplinary Perspectives on the Co-Management of Metabolic Dysfunction-Associated Steatotic Liver Disease and Coronary Artery Disease

AU - Gries, Jacob J.

AU - Lazarus, Jeffrey V.

AU - Brennan, Paul

AU - Siddiqui, Mohammad S.

AU - Targher, Giovanni

AU - Lang, Chim

AU - Virani, Salim S.

AU - Lavie, Carl J.

AU - Isaacs, Scott

AU - Arab, Juan Pablo

AU - Cusi, Kenneth

AU - Krittanawong, Chayakrit

N1 - Publisher Copyright: © 2025 Elsevier Ltd

PY - 2025/1

Y1 - 2025/1

N2 - Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as a public health threat as it affects approximately 38% of the adult population worldwide, with its prevalence rising in step with that of obesity and type 2 diabetes (T2D). Beyond its liver health implications, MASLD is associated with cardiovascular and vascular dysfunction. Although the many shared risk factors and common metabolic milieu may indicate that cardiovascular disease and MASLD are discrete outcomes from common systemic pathogeneses, a growing body of evidence has identified a potential causal relationship between MASLD and coronary artery disease (CAD), which is the leading cause of morbidity and mortality in people with MASLD and all-cause mortality worldwide. This narrative review takes an interdisciplinary approach, drawing on hepatology, cardiology, endocrinology, and metabolic and internal medicine specialists to help delineate the intricate interplay between MASLD and CAD. It sheds light on novel opportunities for targeted interventions and personalized management strategies.

AB - Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as a public health threat as it affects approximately 38% of the adult population worldwide, with its prevalence rising in step with that of obesity and type 2 diabetes (T2D). Beyond its liver health implications, MASLD is associated with cardiovascular and vascular dysfunction. Although the many shared risk factors and common metabolic milieu may indicate that cardiovascular disease and MASLD are discrete outcomes from common systemic pathogeneses, a growing body of evidence has identified a potential causal relationship between MASLD and coronary artery disease (CAD), which is the leading cause of morbidity and mortality in people with MASLD and all-cause mortality worldwide. This narrative review takes an interdisciplinary approach, drawing on hepatology, cardiology, endocrinology, and metabolic and internal medicine specialists to help delineate the intricate interplay between MASLD and CAD. It sheds light on novel opportunities for targeted interventions and personalized management strategies.

UR - https://www.scopus.com/pages/publications/85211455545

U2 - 10.1016/S2468-1253(24)00310-8

DO - 10.1016/S2468-1253(24)00310-8

M3 - Review article

C2 - 39674228

SN - 2468-1253

VL - 10

SP - 82

EP - 94

JO - The Lancet Gastroenterology and Hepatology

JF - The Lancet Gastroenterology and Hepatology

IS - 1

ER -